SEECancer: a resource for somatic events in evolution of cancer genome

Abstract Cancer cells progressively evolve from a premalignant to a malignant state, which is driven by accumulating somatic alterations that confer normal cells a fitness advantage. Improvements in high-throughput sequencing techniques have led to an increase in construction of tumor phylogenetics and identification of somatic driver events that specifically occurred in different tumor progression stages. Here, we developed the SEECancer database (http://biocc.hrbmu.edu.cn/SEECancer), which aims to present the comprehensive cancer evolutionary stage-specific somatic events (including early-specific, late-specific, relapse-specific, metastasis-specific, drug-resistant and drug-induced genomic events) and their temporal orders. By manually curating over 10 000 published articles, 1231 evolutionary stage-specific genomic events and 5772 temporal orders involving 82 human cancers and 23 tissue origins were collected and deposited in the SEECancer database. Each entry contains the somatic event, evolutionary stage, cancer type, detection approach and relevant evidence. SEECancer provides a user-friendly interface for browsing, searching and downloading evolutionary stage-specific somatic events and temporal relationships in various cancers. With increasing attention on cancer genome evolution, the necessary information in SEECancer will facilitate understanding of cancer etiology and development of evolutionary therapeutics, and help clinicians to discover biomarkers for monitoring tumor progression.

[1]  J. Salk.  Clonal evolution in cancer , 2010 .

[2]  Víctor Quesada,et al.  Molecular pathogenesis of CLL and its evolution , 2015, International Journal of Hematology.

[3]  Irving L. Weissman,et al.  Human Acute Myeloid Leukemia Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes , 2012 .

[4]  P. A. Futreal,et al.  Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing , 2014, Nature Genetics.

[5]  Charles Swanton,et al.  Implications of cancer evolution for drug development , 2017, Nature Reviews Drug Discovery.

[6]  Luca Laurenti,et al.  Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia , 2014, eLife.

[7]  Mingming Jia,et al.  COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..

[8]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[9]  R. Majeti,et al.  Pre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesis , 2014, Leukemia.

[10]  Zemin Zhang,et al.  Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.

[11]  J. Welch,et al.  Mutation position within evolutionary subclonal architecture in AML. , 2014, Seminars in hematology.

[12]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[13]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[14]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[15]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[16]  Rebecca A Betensky,et al.  Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.

[17]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[18]  Raul Rabadan,et al.  Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. , 2013, Blood.

[19]  Helen Parker,et al.  The mutational signature of chronic lymphocytic leukemia. , 2016, The Biochemical journal.

[20]  Wei-Chung Cheng,et al.  DriverDBv2: a database for human cancer driver gene research , 2015, Nucleic Acids Res..

[21]  F. Chisari,et al.  Multiple oncogenes and tumor suppressor genes are structurally and functionally intact during hepatocarcinogenesis in hepatitis B virus transgenic mice. , 1992, Cancer research.

[22]  Jong-Ho Won,et al.  DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  Carlos Caldas,et al.  The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.

[24]  Charles Swanton,et al.  Cancer: evolution within a lifetime. , 2014, Annual review of genetics.

[25]  P. Gimenez-Bonafe,et al.  Overcoming drug resistance by enhancing apoptosis of tumor cells. , 2009, Current cancer drug targets.

[26]  E. Solary,et al.  An evolutionary perspective on chronic myelomonocytic leukemia , 2013, Leukemia.

[27]  Paola Guglielmelli,et al.  Effect of mutation order on myeloproliferative neoplasms. , 2015, The New England journal of medicine.

[28]  S-H Jung,et al.  Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression , 2016, Leukemia.

[29]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[30]  F. Cleton.  Evolution of Cancer , 1991, British Journal of Cancer.

[31]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[32]  Gary D Bader,et al.  International network of cancer genome projects , 2010, Nature.

[33]  Li Wang,et al.  Cooperative genomic alteration network reveals molecular classification across 12 major cancer types , 2016, Nucleic acids research.

[34]  M. Stratton,et al.  High burden and pervasive positive selection of somatic mutations in normal human skin , 2015, Science.

[35]  Francesco Favero,et al.  Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution , 2014, Genome Biology.

[36]  Peter J. Campbell,et al.  Evolution of the cancer genome , 2012, Nature Reviews Genetics.

[37]  Francis S. Collins,et al.  Mapping the cancer genome , 2007 .

[38]  Satoru Miyano,et al.  Acquired initiating mutations in early hematopoietic cells of CLL patients. , 2014, Cancer discovery.

[39]  Peiyong Guan,et al.  The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma , 2017, Nature Communications.

[40]  Charles Swanton,et al.  Cancer evolution constrained by mutation order. , 2015, New England Journal of Medicine.

[41]  J. Campisi.  Aging, cellular senescence, and cancer. , 2013, Annual review of physiology.

[42]  Thierry Soussi,et al.  TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes , 2016, International journal of cancer.

[43]  S. Fröhling,et al.  Preview : Published ahead of advance online publication Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia , 2015 .

[44]  F. Delhommeau,et al.  Effect of mutation order on myeloproliferative neoplasms. , 2015, The New England journal of medicine.

[45]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[46]  Francis S Collins,et al.  Mapping the cancer genome. Pinpointing the genes involved in cancer will help chart a new course across the complex landscape of human malignancies. , 2007, Scientific American.

[47]  D. Landau,et al.  Genetic and epigenetic determinants of B-cell lymphoma evolution , 2016, Current opinion in hematology.